A paradigm shift within the therapy of persistent lymphocytic leukemia (CLL) has taken place over the previous decade, as therapies have progressed from offering palliative aid to inducing full remission, eradicating minimal illness and bettering survival. The event of Rituxan® (rituximab) and its use in immunochemotherapy regimens has remodeled the therapy of CLL and...
